Valuation: Jasper Therapeutics, Inc.

Market Cap 11.79M 10.32M 9.52M 8.88M 16.74M 1.11B 17.04M 114M 44.35M 550M 44.28M 43.29M 1.92B P/E 2026 *
-0.45x
P/E 2027 * -0.32x
Enterprise Value -271M -237M -219M -204M -384M -25.58B -391M -2.62B -1.02B -12.62B -1.02B -994M -43.98B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.81%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Jasper Therapeutics, Inc.

1 day+0.29%
1 week-13.91%
1 month-49.22%
3 months-51.95%
6 months-76.99%
Current year-76.99%
1 week 0.32
Extreme 0.3151
0.52
1 month 0.32
Extreme 0.3151
0.64
Current year 0.32
Extreme 0.3151
2.07
1 year 0.32
Extreme 0.3151
7.19
3 years 0.32
Extreme 0.3151
31.01
5 years 0.32
Extreme 0.3151
188.8
10 years 0.32
Extreme 0.3151
188.8
Manager TitleAgeSince
Chief Executive Officer 54 2026-01-05
Director of Finance/CFO 54 2023-09-21
Chief Tech/Sci/R&D Officer 68 2023-03-22
Director TitleAgeSince
Director/Board Member 54 2026-01-05
Director/Board Member 70 2021-09-03
Director/Board Member 58 2021-09-23
Date Insider Type Main position Quantity % Market Cap.
02-05Free

Chief Executive Officer

500,000 1.7867%
01-01Free

Chief Executive Officer

90,000 0.3216%
01-01Free

Chief Financial Officer

90,000 0.3216%
Change 5-day change 1-year change 3-year change Capi.($)
+0.29%-13.91%-92.41%-96.93% 11.79M
+0.22%+8.60%+70.98%+132.68% 57.65B
-1.32%+17.12%+79.02%+99.82% 55.14B
-1.28%+2.68%-12.60%-13.79% 23.53B
+1.79%+4.38%+5.94%+405.31% 23.11B
-1.93%+11.11%+34.89%-7.86% 18.14B
+0.70%+5.16%+36.48%-30.81% 16.84B
+0.24%+5.98%+23.45%+184.72% 13.68B
+0.14%+9.60%+33.31% - 12.97B
+1.83%+4.58%+77.42%+132.45% 12.38B
Average +0.06%+3.72%+25.65%+89.51% 23.35B
Weighted average by Cap. -0.20%+4.87%+48.18%+116.56%

Financials

2026 *2027 *
Net sales - -
Net income -36.99M -32.38M -29.89M -27.88M -52.53M -3.5B -53.47M -359M -139M -1.73B -139M -136M -6.01B -64.38M -56.35M -52.02M -48.52M -91.42M -6.09B -93.06M -624M -242M -3B -242M -236M -10.46B
Net Debt -282M -247M -228M -213M -401M -26.7B -408M -2.74B -1.06B -13.17B -1.06B -1.04B -45.9B -555M -485M -448M -418M -788M -52.44B -802M -5.38B -2.09B -25.88B -2.08B -2.04B -90.15B
Logo Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.
Employees
22
Date Price Change Volume
26-06-30 US$0.4210 +0.29% 266,512
26-06-29 US$0.4198 +23.11% 974,759
26-06-26 US$0.3410 -22.99% 1,353,034
26-06-25 US$0.4428 -9.74% 319,885
26-06-24 US$0.4906 +0.33% 279,370
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
0.4210USD
Average target price
8.625USD
Spread / Average Target
+1,948.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JSPR Stock